USA flag logo/image

An Official Website of the United States Government

Antibody-Biocide Fusions to Control Cryptosporidium

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66056
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI056944
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
IOGENETICS, LLC
IOGENETICS, LLC 3591 ANDERSON ST, #218 MADISON, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: Antibody-Biocide Fusions to Control Cryptosporidium
Agency: HHS
Contract: 2R44AI056944-06
Award Amount: $2,997,508.00
 

Abstract:

DESCRIPTION (provided by applicant): Cryptosporidiosis is a leading cause of diarrheal disease worldwide and is a category B biothreat agent. Two major species, Cryptosporidium hominis and Cryptosporidium parvum are responsible for over ninety percent of c ases in man. C. parvum is zoonotic, with a reservoir in cattle, where it is an economically important cause of disease. There is currently no specific drug for cryptosporidiosis. The goal of this project is to bring to the point of readiness for out-licens ing Directed BiocideTM therapeutics which target Cryptosporidium species affecting man and livestock and which are effective in oral treatment of cryptosporidiosis. The Directed BiocideTM approach creates a recombinant fusion protein in which an antibody t argeting a surface epitope on Cryptosporidium sporozoites delivers an anticryptosporidial biocide comprising a natural antimicrobial peptide or enzyme to the surface of the sporozoite. With this approach Directed BiocideTM products are effective at far low er concentrations than a sporozoite-neutralizing antibody acting alone. Additional Directed BiocidesTM will be developed to target all causal species of human cryptosporidiosis, including C. hominis, and will be tested in vitro and in multiple animal model s. Purification strategies will be established for these novel fusion protein products which will be suitable for human use products. The project also continues research to produce anticryptosporidial Directed BiocidesTM in milk of transgenic cattle for or al treatment of livestock or large populations. PUBLIC HEALTH RELEVANCE: Cryptosporidiosis is one of the most important causes of diarrheal disease worldwide, affecting both immunocompromised and immunocompetent individuals and sometimes causing mass outbr eaks. Cryptosporidium is a Category B biothreat agent. Currently there is no effective drug available for cryptosporidiosis. This project develops a novel recombinant protein drug to neutralize the two species of Cryptosporidium that are responsible for ov er 90% of cases affecting humans.

Principal Investigator:

Michael Imboden
6083109543
MICHAEL_IMBODEN@IOGENETICS.COM

Business Contact:

Jane Homan
jane_homan@iogenetics.com
Small Business Information at Submission:

IOGENETICS, LLC
IOGENETICS, LLC 3591 ANDERSON ST, #218 MADISON, WI 53704

EIN/Tax ID: 391986261
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No